For the year ending 2025-12-31, BDTX made $70M in revenue. $22.444M in net income. Net profit margin of 32.06%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| License revenue | 70 | |||
| Research and development | 33.558 | |||
| General and administrative | 16.572 | |||
| Impairment of right-of-use assets and property and equipment | 7.348 | |||
| Total operating expenses | 57.478 | |||
| Income (loss) from operations | 12.522 | |||
| Interest income | 4.061 | |||
| Other income (expense) | 5.784 | |||
| Total other income (expense), net | 9.845 | |||
| Net income (loss) | 22.367 | |||
| Change in unrealized (loss) gain on investments, net | 0.077 | |||
| Comprehensive income (loss) | 22.444 | |||
| Basic EPS | 0.39 | |||
| Diluted EPS | 0.39 | |||
| Basic Average Shares | 56,868,111 | |||
| Diluted Average Shares | 57,562,746 | |||
Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. (BDTX)